Thus, the development of phosphatase inhibitors with similar selectivity for PTP1B and TC-PTP may become a promising direction for the development of drugs for the correction of hyperphagia and obesity and the treatment of metabolic disorders, such as type 2 diabetes mellitus and metabolic syndromes. This evidence concerns the gene PTPN1 and metabolic disease.